Vol 119, No 1 (Supplement) 2014
Supplement abstract

Gc-protein-derived Macrophage Activating Factor (GcMAF) induces ERBB2 shift in human breast cancer

Published 2015-03-19

Keywords

  • Breast cancer,
  • GcMAF,
  • immunotherapy,
  • oncogene

How to Cite

Ruggiero, M., Gulisano, M., Noakes, D., Branca, J. J., Morucci, G., & Pacini, S. (2015). Gc-protein-derived Macrophage Activating Factor (GcMAF) induces ERBB2 shift in human breast cancer. Italian Journal of Anatomy and Embryology, 119(1), 169. Retrieved from https://oajournals.fupress.net/index.php/ijae/article/view/2522

Abstract

HER2/Neu/ERBB2 is a receptor tyrosine kinase overexpressed in a high percentage of human breast cancers. Gc-protein-derived Macrophage Activating Factor (GcMAF) is a powerful stimulant of the immune system endowed with intrinsic anticancer properties (Pacini et al., 2012). We recently demonstrated that molecular complexes of oleic acid (OA) and GcMAF (OA-GcMAF) show significant therapeutic activity in a variety of tumours (Ward et al., 2014). Here we demonstrate that OAGcMAF eradicates ERBB2 expression in human breast cancer. A biopsy taken before OA-GcMAF treatment showed strong positivity to ERBB2. The patient was then treated with OA-GcMAF administered through subcutaneous injections and with food naturally rich in OA-GcMAF for 3 weeks prior to mastectomy. The subsequent surgery specimen was negative for ERBB2. These results lead to hypothesize: 1. OAGcMAF completely reversed the neoplastic phenotype. 2. OA-GcMAF induced the apoptosis of all ERBB2-positive cancer cells.